213 related articles for article (PubMed ID: 28954274)
1. Lymphopenia and CD4+/CD8+ Cell Reduction under Fumaric Acid Esters.
Sondermann W; Rompoti N; Leister L; Huptas L; Klode J; Dissemond J; Körber A
Dermatology; 2017; 233(4):295-302. PubMed ID: 28954274
[TBL] [Abstract][Full Text] [Related]
2. Fumaric acid ester-induced T-cell lymphopenia in the real-life treatment of psoriasis.
Dickel H; Bruckner T; Höxtermann S; Dickel B; Trinder E; Altmeyer P
J Eur Acad Dermatol Venereol; 2019 May; 33(5):893-905. PubMed ID: 30680823
[TBL] [Abstract][Full Text] [Related]
3. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis.
Höxtermann S; Nüchel C; Altmeyer P
Dermatology; 1998; 196(2):223-30. PubMed ID: 9568412
[TBL] [Abstract][Full Text] [Related]
4. A case series of persistent lymphopaenia following treatment with fumaric acid esters for psoriasis.
Beatty PE; Killion L; Callaghan G; Tierney E; Kelly G; Tobin AM
J Clin Pharm Ther; 2021 Jun; 46(3):859-861. PubMed ID: 33432649
[TBL] [Abstract][Full Text] [Related]
5. The Implications of Recent Recommendations for Managing Patients with Psoriasis Treated with Fumaric Acid Esters.
Foley CC; Molloy OE; Lally A; Kirby B
Dermatology; 2017; 233(2-3):175-177. PubMed ID: 28869956
[TBL] [Abstract][Full Text] [Related]
6. Immunological changes in psoriasis patients under long-term treatment with fumaric acid esters: risk of Kaposi sarcoma occurrence?
Philipp S; Kokolakis G; Hund M; Witte E; Witte K; Kunz S; Roewert HJ; Sterry W; Sabat R
Eur J Dermatol; 2013; 23(3):339-43. PubMed ID: 23774790
[TBL] [Abstract][Full Text] [Related]
7. Lymphopenia and fumaric acid esters for psoriasis: a retrospective case series prompted by the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) recommendations.
Roche L; Lynch M; Ahmad K; Hackett C; Ramsay B
Clin Exp Dermatol; 2018 Jan; 43(1):72-75. PubMed ID: 29027699
[No Abstract] [Full Text] [Related]
8. Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study.
Wain EM; Darling MI; Pleass RD; Barker JN; Smith CH
Br J Dermatol; 2010 Feb; 162(2):427-34. PubMed ID: 19519838
[TBL] [Abstract][Full Text] [Related]
9. Progressive multifocal leukoencephalopathy associated with fumaric acid esters treatment in psoriasis patients.
Balak DMW; Hajdarbegovic E; Bramer WM; Neumann HAM; Thio HB
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1475-1482. PubMed ID: 28322482
[TBL] [Abstract][Full Text] [Related]
10. Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study.
Dickel H; Bruckner T; Altmeyer P
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1710-1727. PubMed ID: 29705996
[TBL] [Abstract][Full Text] [Related]
11. Significant CD4, CD8, and CD19 lymphopenia in peripheral blood of sarcoidosis patients correlates with severe disease manifestations.
Sweiss NJ; Salloum R; Gandhi S; Alegre ML; Sawaqed R; Badaracco M; Pursell K; Pitrak D; Baughman RP; Moller DR; Garcia JG; Niewold TB
PLoS One; 2010 Feb; 5(2):e9088. PubMed ID: 20140091
[TBL] [Abstract][Full Text] [Related]
12. Fumaric acid esters for psoriasis: a systematic review.
Smith D
Ir J Med Sci; 2017 Feb; 186(1):161-177. PubMed ID: 27271164
[TBL] [Abstract][Full Text] [Related]
13. Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases.
Harries MJ; Chalmers RJ; Griffiths CE
Br J Dermatol; 2005 Sep; 153(3):549-51. PubMed ID: 16120141
[TBL] [Abstract][Full Text] [Related]
14. 24-hour immunologic assessment of CD4+ and CD8+ lymphocytes in renal transplant recipients receiving chronic methylprednisolone.
Tornatore KM; Reed K; Venuto R
Clin Nephrol; 1995 Nov; 44(5):290-8. PubMed ID: 8605708
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis.
Hoefnagel JJ; Thio HB; Willemze R; Bouwes Bavinck JN
Br J Dermatol; 2003 Aug; 149(2):363-9. PubMed ID: 12932244
[TBL] [Abstract][Full Text] [Related]
16. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference.
Mrowietz U; Christophers E; Altmeyer P
Br J Dermatol; 1999 Sep; 141(3):424-9. PubMed ID: 10584060
[TBL] [Abstract][Full Text] [Related]
17. Fumaric acid esters in the management of severe psoriasis.
Brewer L; Rogers S
Clin Exp Dermatol; 2007 May; 32(3):246-9. PubMed ID: 17362235
[TBL] [Abstract][Full Text] [Related]
18. Fumaric acid esters (FAEs) suppress CD 15- and ODP 4-positive cells in psoriasis.
Bacharach-Buhles M; Pawlak FM; Matthes U; Joshi RK; Altmeyer P
Acta Derm Venereol Suppl (Stockh); 1994; 186():79-82. PubMed ID: 7915483
[TBL] [Abstract][Full Text] [Related]
19. CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure.
Tornatore KM; Venuto RC; Logue G; Davis PJ
J Med; 1998; 29(3-4):159-83. PubMed ID: 9865456
[TBL] [Abstract][Full Text] [Related]
20. Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases.
Gieselbach RJ; Muller-Hansma AH; Wijburg MT; de Bruin-Weller MS; van Oosten BW; Nieuwkamp DJ; Coenjaerts FE; Wattjes MP; Murk JL
J Neurol; 2017 Jun; 264(6):1155-1164. PubMed ID: 28536921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
